Published in final edited form as:

Gynecol Oncol. 2017 February ; 144(2): 391–395. doi:10.1016/j.ygyno.2016.11.031.

Trends in cervical cancer incidence in younger US women from 2000-2013

Daniel C. Beachler, PhD, MHS, Joseph E. Tota, PhD, MSC, Michelle I. Silver, PhD, ScM, Aimée R. Kreimer, PhD, MS, Allan Hildesheim, PhD, Nicolas Wentzensen, MD, PhD, Mark Schiffman, MD, MPH, and Meredith S. Shiels, PhD, MHS

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA

Abstract

Objective—This study aimed to assess the temporal trends in invasive cervical cancer (ICC) incidence rates among 21-25 year-olds. US guidelines no longer recommend screening prior to age 21, and concerns have been raised that delayed screening initiation may increase ICC incidence among young women.

Methods—This study utilized ICC incidence data from 18 US population-based cancer registries in SEER from 2000-2013 and Pap test prevalence data from the Behavioral Risk Factor Surveillance System from 1996-2012. Trends were evaluated with annual percent changes (APCs) using Joinpoint regression.

Results—The prevalence of never having a Pap test before age 21 increased from 22.0% in 1996-2004 to 38.3% in 2006-2012 (APC= +5.48, 95%CI=+4.20, +7.50). Despite this decline in screening, ICC incidence among 21-23 year olds significantly declined between 2000-13 (APC= -5.36, 95%CI=-7.83, -2.82), particularly from 2006-2013 (APC= -9.70, 95%CI=-15.79, -3.17). ICC incidence remained constant among 24-25 year olds (APC= +0.45, 95%CI=-2.00, 2.97). Compared to women born in 1978-1985, women born in 1986-1991 had a higher prevalence of never receiving a Pap test prior to 21 (35.4% vs. 22.1%, $p<0.001$), but a lower ICC incidence at 21-23 (0.98 vs. 1.55 per 100,000, $p<0.001$).

Conclusion—While US females born in 1986-1991 were less likely to receive a Pap test before age 21, diagnoses of ICC in the early 20s were rare and lower than for those born in earlier years. This provides reassurance that the updated guidelines to delay screening until 21 has not resulted in a population-level increase in ICC rates among young women.

Corresponding author: Daniel C. Beachler, PhD, MHS, National Cancer Institute, 9609 Medical Center Drive, RM 6-E220, Bethesda, MD 20892, P: 717-514-5540, daniel.beachler@nih.gov.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflicts of Interest:

The authors report no conflicts of interest.

IRB approval:

This study uses de-identified data provided in the National Cancer Institute's SEER database. The National Institute of Health's Office of Human Subjects Research Protections considers that this research does not involve human subjects and that it is therefore exempt from human subjects review.

Introduction

US cervical cancer screening guidelines have increasingly recommended against Pap testing among women younger than 21 years old. Prior to 2002, the guidelines were to begin screening at age 18 or with the onset of sexual intercourse.[1] In 2002-2003, the American Cancer Society, American Congress of Obstetricians and Gynecologists (ACOG), and US Preventive Services Task Force (USPSTF) recommended screening initiation at age 21 or three years after the onset of vaginal intercourse. In 2009, ACOG recommended screening at age 21 regardless of sexual history; other organizations had adopted this guideline by 2012. [1-5]

Reflecting these evolving guidelines, the percentage of 18-20 year old women who never had a Pap test has nearly doubled from 2000-2010.[6] Cervical cancer is rarely diagnosed at younger ages, but concern has been raised that not screening and treating pre-cancerous lesions prior to age 21 could result in increased risk of invasive cervical cancer (ICC) among 21-25 year olds.[7]

While previous studies report that ICC incidence rates in young women have declined over the past several decades,[8] more recent trends have not been explored. Given the decline in screening uptake prior to age 21, it is important to examine recent ICC incidence rates in younger women. We utilized US population-based data to assess Pap test prevalence and ICC incidence rates over time among 21-35 year-old women.

Methods

Cancer/Pap testing data

The primary outcome of this study was incident invasive cervical cancer (ICC). ICC incidence data was evaluated during 2000-2013 from 18 population-based cancer registries from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program. SEER represents ~28% of the US population and has reliable and detailed ascertainment of cancer diagnoses.[9] ICCs were defined using ICD-0-3 codes C53.0-C53.9 and restricted to microscopically-confirmed, invasive cases.[10] Stage was categorized using SEER summary stage,[11] and histology was defined with the IARC classification using ICD-0-3 histology codes as squamous cell carcinoma, adenocarcinoma or other.[12] The other category includes other specified carcinoma, unspecified carcinoma, sarcoma, other specified malignant neoplasm, and unspecified malignant neoplasms. [12]

The Centers for Disease Control and Prevention's Behavioral Risk Factor Surveillance System (BRFSS) was used to estimate the US trends of Pap testing from 1996-2012. The BRFSS is a cross-sectional, phone-based survey that provides nationally-representative estimates of risk factors. Every other year from 1996-2012, the BRFSS asked >1,500 20 and 23 year-old women: "A Pap test is a test for cancer of the cervix. Have you ever had a Pap test?" We utilized survey weights to account for the complex sampling design. From 1996-2010 the survey weights were developed through post stratification, while in 2012 the weights were developed through iterative proportional fitting which accounts for the supplemental cell phone use that was added in 2011.[13] We evaluated the weighted

percentage of women aged 20 and aged 23 who reported never having a Pap test (i.e., no pap test prior to age 21 and 24, respectively).[14,15] States included in SEER were dichotomized as having Pap test uptake prevalence above or below the median at ages 20 and 23 in 2010.

Statistical Analysis

ICC incidence rates per 100,000 woman-years were age-standardized using the 2000 US standard population. ICC incidence was stratified by age group (21-25, 26-30, and 31-35 year-olds), while women aged 21-25 years were further stratified into 21-23 and 24-25 year-olds. Rates were also stratified by cancer stage, histology, and race. Annual percent changes (APCs) in age-standardized ICC incidence and Pap testing prevalence were evaluated over calendar year and year of birth with were estimated with Joinpoint regression.[16] To assess whether trends in ICC rates among 21-23 year-olds were influenced by contemporaneous declines in Pap testing prevalence in this age group, we carried out a sensitivity analysis. We assumed that all ICC cases were diagnosed among women screened with Pap testing and adjusted the rate denominator for each year to represent the estimated screened population (i.e., adjusted denominator=Pap testing prevalence at age 23*general population in SEER areas).

Results

US ICC incidence trends from 2000-2013

During 2000-2013, 766 cases of ICC occurred in women aged 21-25 years (IR=1.87 per 100,000 person-years, 95%CI= 1.74, 2.01 per 100,000 person-years). The majority of cases were squamous cell carcinoma (68.8%) and local stage at diagnosis (68.4%) (Table 1). The age-standardized ICC incidence among 21-25 year old women significantly declined (APC= -1.94%/year, 95%CI= -3.42, -0.44) during 2000-2013; from 2.02 per 100,000 in 2000-2004 to 1.71 per 100,000 in 2009-2013 (Figure 1). Similarly, ICC incidence significantly declined in 26-30 year-olds (APC= -3.40%/year, 95%CI= -4.55, -2.23) and 31-35 year-olds (APC= -1.75%/year, 95%CI= -2.54, -0.95) during 2000-2013 (Figure 1).

The decline in ICC incidence among 21-25 year-old women was driven by a steeper decline among 21-23 year-olds (eFigure 1; APC= -5.36%/year, 95%CI= -7.83, -2.82), while remaining constant among 24-25 year-olds (APC= +0.45%/year, 95%CI= -2.00, +2.97). The decline in ICC incidence among 21-23 year-olds primarily occurred in 2006-2013 (APC= -9.70%/year, 95%CI= -15.79, -3.17). The APC was not significant when restricted to 2000-2006 (APC= +0.32%/year, 95%CI= -8.16, +9.57; joinpoint p-value=0.09). The trends in ICC incidence were similar by histology, stage, and race in both 21-23 and 24-25 year-olds (Table 1).

Pap testing trends in the US

The prevalence of never having a Pap test prior to age 21 significantly increased during 1996-2012 (APC= +5.84%/year, 95%CI=+4.25, +7.47; eTable 1 in the Supplement) from 22.0% in 1996-2004 to 38.3% in 2006-2012 (p<0.01). In addition, the prevalence of never having a Pap test prior to age 24 significantly increased between 1996-2012 (APC= +4.47%/

year, 95%CI= +2.33, +6.65) from 9.6% in 1996-2004 to 13.8% in 2006-2012 (eTable 1 in the Supplement).

ICC incidence and Pap test trends by birth cohort

Figure 2 presents ICC incidence rates and prevalence of never having a Pap test within age groups across birth cohorts. Compared to women born in 1978-1985, women born in 1986-1991 were more likely to not receive a Pap test prior to age 21 (35.4% vs. 22.1%; $p<0.001$), but were less likely to be diagnosed with ICC at ages 21-23 (0.98 vs. 1.55 per 100,000; $p<0.001$; Figure 2).

The decline in ICC incidence in 21-23 year-old women was similar in states with lower and higher reported Pap uptake prior to age 21 (Table 1). In a sensitivity analysis, the ICC incidence decline in 21-23 year olds was similar when restricting the denominator of the incidence rate to the estimated screened population with rates declining from 1.66 to 1.13 per 100,000 in 2000-2008 to 2009-2013.

Discussion

Similar to other guidelines,[1-3,17] the USPSTF suggests that there is moderate certainty that the harms of Pap testing prior to age 21 outweigh the benefits.[4] These recently updated guidelines likely have led to the decline in Pap testing before age 21 in young women born in the late 1980s and early 1990s as observed in this study and others.[6,18,19] This study provides reassurance that population-level increases in ICC incidence have not occurred among young women despite an increasing fraction of women delaying Pap testing until age 21 years or older.

There are several potential explanations for declining ICC rates among 21-23 year-old women. These declines could be due in part to lack of detection of asymptomatic local stage ICCs among the growing unscreened population, as a large fraction of these ICCs are likely detected through Pap testing. However, most women born in the late 1980s and early 1990s were still screened in their early 20s, and our analyses restricting to the estimated population of women who were screened suggested similar trends. Nonetheless, future studies are needed to confirm that the declining cancer incidence is not attributable to reduced screening at ages 21-23 and to confirm that future ICC incidence at older ages (i.e. 26-35) is not subsequently elevated in those born in the late 1980s and early 1990s.

Approximately 25% of women born in the late 1980s received at least one dose of the HPV vaccine by 2012.[20] Studies have found that the vaccine strongly protects against HPV acquisition,[21,22] but does not impact HPV clearance or disease regression;[23] and that most ICCs do not develop for at least one decade after HPV acquisition.[24,25] The vaccine was approved in 2006, seven years prior to our end of follow-up. The impact of vaccination on the declines in early-onset ICC incidence rates is difficult to quantify, as little is known about the latency of these rare early-onset malignancies. An examination of the recent trends in early-onset ICC incidence in other countries with higher HPV vaccine uptake could be informative.

Alternatively, other population-level changes including those related to sexual behavior and the acquisition of HPV may partially explain the reduction in ICC. Women have been modestly less likely to become sexually active in their teens in recent years (43% in 2006-2010 vs. 49% in 1995),[26] and a recent report suggests that childhood sexual abuse declined in the US over the last two decades.[27]

The main strength of this study is the use of large, population-based data on ICC incidence rates in parallel with Pap testing prevalence data in young women from the US. Our study was limited by its ecologic design, as we were unable to directly link the self-reported screening behavior and cancer incidence at the individual level. There may be misclassification in the self-reported screening as women may equate having a pelvic exam as having a Pap smear or may assume a test was not done if they were never informed of a result; however this potential misclassification is likely to be non-differential across time. In addition, the landline and cell phone response rates for the BRFSS have been limited over the past decade, although other surveys such as the household-based US National Health Interview Survey (NHIS) have also observed a decline in pap testing among young US women in recent years. [18]

This study shows that ICC incidence rates among 21-25 year olds are very low, and have not increased in recent years, even in birth cohorts where Pap testing prior to age 21 was less prevalent. These data provide reassurance that the adoption of US guidelines recommending the delay of Pap testing until age 21 has not resulted in population-level increases in ICC incidence in young women, with ICC incidence rates remaining well below those of other cancers where screening is recommended. Furthermore, it should be noted that while screening uptake has been declining in recent years, more than half of U.S. women still received a Pap test prior to age 21 in 2012 despite the guideline recommendations.

Continued monitoring of ICC incidence rates in millennial women with lower screening rates is important, especially in future years when they will be at ages (30s and 40s) when cervical cancer is more common. Additionally, monitoring of ICC rates is particularly necessary if organizations plan to issue future guidelines to further delay the age of screening initiation in response to vaccine uptake.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Source of funding:

This work was supported by the Intramural Research Program of the National Cancer Institute.

References

1. Waxman AG. Guidelines for cervical cancer screening: history and scientific rationale. Clin.Obstet.Gynecol. Mar.2005 48:77–97. [PubMed: 15725861]
2. ACOG Committee on Practice Bulletins--Gynecology. ACOG Practice Bulletin no. 109: Cervical cytology screening. Obstet.Gynecol. Dec.2009 114:1409–1420. [PubMed: 20134296]

3. Ressel GW. American College of Obstetricians and Gynecologists. ACOG releases guidelines on cervical cytology screening. *Am.Fam.Physician.* Nov 15.2003 68:2081. [PubMed: 14655818]
4. Moyer VA, U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. *Ann.Intern.Med.* Jun 19.2012 156:880–91. W312. [PubMed: 22711081]
5. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. *Am.J.Clin.Pathol.* Apr.2012 137:516–542. [PubMed: 22431528]
6. Cervical Cancer Screening Among Women Aged 18–30 Years — United States, 2000–2010. Morbidity and Mortality Weekly Report. 2013; 61:1038–1042. [PubMed: 23282861]
7. Boone E, Lewis L, Karp M. Discontent and Confusion: Primary Care Providers' Opinions and Understanding of Current Cervical Cancer Screening Recommendations. *J.Womens Health.* (Larchmt). Nov 5.2015
8. Kurdgelashvili G, Dores GM, Srouf SA, Chaturvedi AK, Huycke MM, Devesa SS. Incidence of potentially human papillomavirus-related neoplasms in the United States, 1978 to 2007. *Cancer.* Jun 15.2013 119:2291–2299. [PubMed: 23580435]
9. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. *Med.Care.* Aug.2002 40:IV–3-18.
10. Site Recode ICD-O-3/WHO. Definition. 2008. (http://seer.cancer.gov/siterecode/icdo3_dwhoheme/)
11. Young JL, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA. SEER Summary Staging Manual - 2000: Codes and Coding Instructions. 2001
12. Egevad, L.; Heanue, M.; Berney, D.; Fleming, K.; Ferlay, J. Histological groups.. In: Curado, MP.; Edwards, B.; Shin, HR., editors. *Cancer incidence in five continents.* IX ed.. Vol. IX. IARC Scientific Publications; Lyon, France: 2014. p. 61-66. Chapter 4,

13. BRFSS - CDC's Behavioral Risk Factor Surveillance System, Data User Guide. (<http://www.cdc.gov/brfss/>)
14. Tiro JA, Saraiya M, Jain N, Liddon N, Cokkinides V, Lai SM, et al. Human papillomavirus and cervical cancer behavioral surveillance in the US. *Cancer.* Nov 15.2008 113:3013–3030. [PubMed: 18980284]
15. Pierannunzi C, Hu SS, Balluz L. A systematic review of publications assessing reliability and validity of the Behavioral Risk Factor Surveillance System (BRFSS), 2004-2011. *BMC Med.Res.Methodol.* Mar 24.2013 13:49–2288-13-49. [PubMed: 23522349]
16. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. *Stat.Med.* Feb 15.2000 19:335–351. [PubMed: 10649300]
17. Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. *CA Cancer.J.Clin.* Nov-Dec;2002 52:342–362. [PubMed: 12469763]
18. Roland KB, Benard VB, Soman A, Breen N, Kepka D, Saraiya M. Cervical cancer screening among young adult women in the United States. *Cancer Epidemiol.Biomarkers Prev.* Apr.2013 22:580–588. [PubMed: 23355601]
19. Cuzick J, Myers O, Hunt WC, Robertson M, Joste NE, Castle PE, et al. A population-based evaluation of cervical screening in the United States: 2008-2011. *Cancer Epidemiol.Biomarkers Prev.* May.2014 23:765–773. [PubMed: 24302677]
20. Williams WW, Lu PJ, O'Halloran A, Bridges CB, Pilishvili T, Hales CM, et al. Noninfluenza vaccination coverage among adults - United States, 2012. *MMWR Morb.Mortal.Wkly.Rep.* Feb 7.2014 63:95–102. [PubMed: 24500288]
21. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. *N.Engl.J.Med.* May 10.2007 356:1915–1927. [PubMed: 17494925]
22. Herrero R, Wacholder S, Rodriguez AC, Solomon D, Gonzalez P, Kreimer AR, et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based

- randomized clinical trial in Guanacaste, Costa Rica. *Cancer.Discov.* Oct.2011 1:408–419. [PubMed: 22586631]
23. Hildesheim A, Gonzalez P, Kreimer AR, Wacholder S, Schussler J, Rodriguez AC, et al. Impact of Human Papillomavirus (HPV) 16 and 18 Vaccination on Prevalent Infections and Rates of Cervical Lesions After Excisional Treatment. *Am.J.Obstet.Gynecol.* Feb 15.2016
24. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. *Lancet.* Sep 8.2007 370:890–907. [PubMed: 17826171]
25. Vink MA, Bogaards JA, van Kemenade FJ, de Melker HE, Meijer CJ, Berkhof J. Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data. *Am.J.Epidemiol.* Oct 1.2013 178:1161–1169. [PubMed: 23897645]
26. Martinez GM, Abma JC. Sexual Activity, Contraceptive Use, and Childbearing of Teenagers Aged 15-19 in the United States. *NCHS Data Brief.* Jul.2015 (209):1–8.
27. Finkelhor, F.; Jones, L.; Shattuck, A. Updated Trends in Child Maltreatment, 2011. Crimes against Children Research Center; 2013.

Gynecologic Oncology Highlights

- Pap testing before age 21 declined in recent years, suggesting guideline adoption
- ICC incidence rates among 21-25 year olds in the US are very low
- ICC incidence in young women has not increased even in recent birth cohorts
- The delay in screening age hasn't resulted in population-level ICC rate increases

Figure 1. Invasive cervical cancer incidence rates over time in US women ages 21-35 years from 2000-2013

ICC incidence rates were age-standardized to the 2000 U.S. population. The incidence rates per 100,000 women are displayed on a log scale. Annual percent changes (APCs) for 21-25, 26-30, and 31-35 year old women marked with asterisks as all significantly ($p < 0.05$) declined between 2000 and 2013.

Figure 2. Invasive cervical cancer (ICC) incidence rates and Pap test trends by year of birth

ICC incidence rates were age-standardized to the 2000 U.S. population. The incidence rates per 100,000 women among 21-23 and 24-25 year old women are displayed on a log scale. The Annual percent change (APC) for 21-23 year old women is marked with an asterisk as it significantly ($p < 0.05$) declined in women born in 1978 to those born in 1991 (i.e. in 2000-2013). The prevalence of not receiving a pap test prior to age 21 over time are presented as gray bars and are described on the second y-axis on the right. The prevalence of not receiving a pap test prior to 21 remained constant for those born in 1976-1980 (APC = -3.22), but significantly increased between those born in 1980 to 1992 (APC = +7.47, joinpoint p -value = 0.01). ICC incidence data from SEER is only currently available through 2013, when individuals born in 1988 were 25. Thus, ICC incidence between the ages 24-25 are not yet available from those born after 1998.

ICC Incidence Rates (per 100,000) over time among 21-25 year-old women between 2000 and 2013

Table 1

	21-23 year-olds					24-25 year-olds				
	Total n	2000-2004	2005-2008	2009-2013	APC	Total n	2000-2004	2005-2008	2009-2013	APC
ICC Incidence	317	1.53	1.48	0.94	-5.36 ^{*,A}	449	2.79	2.59	2.93	+0.45
Histology										
Squamous	215	1.05	0.94	0.67	-4.93 [*]	312	2.02	1.74	2.01	-0.13
Adenocarcinoma	35	0.15	0.25	0.05	n/a	73	0.40	0.38	0.55	+5.75
Other	67	0.32	0.29	0.22	-6.03	64	0.37	0.47	0.37	-1.32
Stage										
Local	208	1.05	0.95	0.59	-6.32 [*]	316	2.11	1.68	2.05	-0.68
Regional	55	0.22	0.31	0.16	-2.87	86	0.42	0.51	0.65	+4.77
Distant	17	0.09	0.09	0.03	n/a	30	0.16	0.26	0.15	n/a
Unknown/unstaged	37	0.17	0.13	0.15	-7.23	17	0.09	0.15	0.08	n/a
Race										
White	239	1.50	1.62	0.94	-4.92 [*]	346	2.95	2.71	3.08	+0.60
Black	47	1.76	1.47	0.86	-7.13 [*]	66	3.19	3.14	2.59	-2.13
Other	31	1.45	0.60	1.00	n/a	37	1.37	1.33	2.51	n/a
Geographic region										
State with lower pap uptake ages 18-20 ^{\$}	172	1.35	1.40	0.82	-6.63 [*]	251	2.48	2.48	2.80	0.67
State with higher pap uptake ages 18-20 ^{\$}	145	1.79	1.60	1.11	-3.83	198	3.26	2.76	3.14	0.36
State with lower pap uptake ages 21-23 ^{&}	170	1.37	1.36	0.81	-6.15 [*]	256	2.46	2.35	3.14	1.93
State with higher pap uptake ages 21-23 ^{&}	147	1.77	1.66	1.13	-4.28 [*]	193	3.37	3.06	2.59	-1.59

Rates age-standardized to the 2000 U.S. population.

* Significant annual percent change (APC); p-value<0.05

^A Non-significant pinpoint (p=0.08); 2000-2006: APC= 0.32 (95%CI=-8.20, 9.60), 2006-2013: APC= -9.70 (95%CI= -15.80, -3.20).^{\$} 42.9% of 20 year old women never had a pap test in 2010 in lower uptake states in SEER (Alaska, Connecticut, Michigan, California, Iowa, and Utah) compared to 27.3% in other states in SEER (Georgia, Hawaii, Kentucky, Louisiana, New Jersey, New Mexico and Washington).

20.7% of 23 year old women never had a pap test in 2010 in lower uptake states in SEER (Alaska, California, Iowa, Kentucky, New Mexico, and Utah) compared to 11.6% in other states in SEER (Connecticut, Michigan, Georgia, Hawaii, Louisiana, New Jersey, and Washington).